A series of (E)-3-heteroarylidenechroman-4-ones was synthesized.
The compounds were evaluated in vitro as inhibitors of both human MAO isoforms.
All the compounds were found to be selective hMAO-B inhibitors.
The most active compound showed MAO-B inhibitory activity in the nanomolar range.
Docking and molecular dynamics simulations proposed the binding mode of the best compound.